STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma
Four years of sorafenib after curative surgery or ablation for liver cancer did not delay recurrence or lengthen survival, and caused substantial toxicity, closing the door on kinase inhibitors as adjuvant therapy.
Overview
Phase 3 placebo-controlled trial of 1,114 patients with hepatocellular carcinoma after complete resection or ablation randomised to sorafenib or placebo for up to four years.
Median recurrence-free survival was 33.3 versus 33.7 months (hazard ratio 0.94) with no difference in time to recurrence or overall survival, and more than a quarter of sorafenib patients discontinued because of adverse events.
- Median recurrence-free survival 33.3 vs 33.7 months; hazard ratio 0.94.
- Discontinuation for adverse events 24 percent vs 7 percent.
No adjuvant systemic therapy is recommended after curative treatment of hepatocellular carcinoma, a conclusion reinforced by the later failure of IMbrave050.
- Population included patients with relatively low recurrence risk.